[
    [
        {
            "time": "2018-01-02",
            "original_text": "Noteworthy ETF Outflows: MTUM, ABBV, ISRG, SPGI",
            "features": {
                "keywords": [
                    "ETF",
                    "Outflows",
                    "MTUM",
                    "ABBV",
                    "ISRG",
                    "SPGI"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Noteworthy ETF Outflows: MTUM, ABBV, ISRG, SPGI",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Roche's Child Arthritis Drug's New Formulation Gets FDA Nod",
            "features": {
                "keywords": [
                    "Roche",
                    "Child Arthritis",
                    "Drug",
                    "FDA",
                    "Nod"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Roche's Child Arthritis Drug's New Formulation Gets FDA Nod",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Pharma/Biotech Stocks to Watch This Prostate Cancer Month",
            "features": {
                "keywords": [
                    "Pharma",
                    "Biotech",
                    "Stocks",
                    "Prostate Cancer"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma/Biotech Stocks to Watch This Prostate Cancer Month",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Top Stock Reports for JPMorgan, Mastercard & AbbVie",
            "features": {
                "keywords": [
                    "Stock Reports",
                    "JPMorgan",
                    "Mastercard",
                    "AbbVie"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Top Stock Reports for JPMorgan, Mastercard & AbbVie",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "3 Things You Might Be Overlooking With AbbVie",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Overlooking"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "3 Things You Might Be Overlooking With AbbVie",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Roche's Child Arthritis Drug's New Formulation Gets FDA Nod",
            "features": {
                "keywords": [
                    "Roche",
                    "Child Arthritis",
                    "Drug",
                    "FDA",
                    "Nod"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Roche's Child Arthritis Drug's New Formulation Gets FDA Nod",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Neurocrine Biosciences: Analysts Are Mostly Positive",
            "features": {
                "keywords": [
                    "Neurocrine Biosciences",
                    "Analysts",
                    "Positive"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Neurocrine Biosciences: Analysts Are Mostly Positive",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Today’s Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals",
            "features": {
                "keywords": [
                    "Research Reports",
                    "Stocks",
                    "AbbVie",
                    "Progenics Pharmaceuticals"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Today’s Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis",
            "features": {
                "keywords": [
                    "Brawl",
                    "AbbVie",
                    "Gilead Sciences",
                    "Arthritis"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Johnson & Johnson Expands Blood Cancer Portfolio with Approval",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Blood Cancer",
                    "Portfolio",
                    "Approval"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Johnson & Johnson Expands Blood Cancer Portfolio with Approval",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]